综述:肝硬化的当前和新兴治疗管理及其并发症
本文为叙述性综述,聚焦肝硬化及其并发症治疗的最新进展,涵盖病因导向治疗、肝性脑病、腹水、肝肾综合征的标准治疗与最新进展,以及化学预防治疗和非疼痛症状管理,结论认为基于证据的药物治疗可改善临床和患者报告结局。
要点
- 病因导向治疗可预防肝硬化及其并发症,包括抗病毒治疗、酒精使用障碍的精神药理学治疗和非酒精性脂肪性肝炎的临床试验。
- 综述肝性脑病、腹水和肝肾综合征的当前标准治疗与最新进展。
- 评估化学预防治疗的前景与不足,并探讨瘙痒、肌肉痉挛、性功能障碍和疲劳等非疼痛症状的治疗。
核心结论
- 通过应用基于证据的药物治疗方法预防和治疗肝硬化并发症,有可能改善肝硬化患者的临床和患者报告结局。
研究设计与样本
- 叙述性文献综述,聚焦肝硬化及其并发症治疗的最新进展。
主要发现
- 综述了预防肝硬化及其并发症的病因导向治疗,包括抗病毒治疗、酒精使用障碍的精神药理学治疗和非酒精性脂肪性肝炎的临床试验现状。
- 综述了肝性脑病、腹水和肝肾综合征管理的当前标准治疗与最新进展。
- 评估了在试验和观察性研究中检验的化学预防治疗的前景与不足,这些治疗可能降低肝细胞癌和肝硬化并发症的风险。
- 探讨了针对肝硬化非疼痛症状的治疗,包括瘙痒、肌肉痉挛、性功能障碍和疲劳。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cirrhosis is increasingly common and morbid. Optimal utilisation of therapeutic strategies to prevent and control the complications of cirrhosis are central to improving clinical and patient-reported outcomes. METHODS: We conducted a narrative review of the literature focusing on the most recent advances. RESULTS: We review the aetiology-focused therapies that can prevent cirrhosis and its complications. These include anti-viral therapies, psychopharmacological therapy for alcohol-use disorder, and the current landscape of clinical trials for non-alcoholic steatohepatitis. We review the current standard of care and latest developments in the management of hepatic encephalopathy (HE), ascites and hepatorenal syndrome. We evaluate the promise and drawbacks of chemopreventative therapies that have been examined in trials and observational studies which may reduce the risk of hepatocellular carcinoma and cirrhosis complications. Finally, we examine the therapies which address the non-pain symptoms of cirrhosis including pruritis, muscle cramps, sexual dysfunction and fatigue. CONCLUSION: The improvement of clinical and patient-reported outcomes for patients with cirrhosis is possible by applying evidence-based pharmacotherapeutic approaches to the prevention and treatment of cirrhosis complications.
引用
- Tapper EB, Ufere NN, Huang DQ, et al. Review article: current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther. 2022. PMID: 35235219. doi:10.1111/apt.16831
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。